Marking a key step towards the market launch and strengthening of Sisram’s premium aesthetics portfolio
HONG KONG, January 5, 2026 /PRNewswire/ — Sisram Medical Ltd (the “Business” Or “Sisram”1696.HK; with its subsidiaries collectively referred to as “Band”), a global wellness group offering energy-based devices (EBDs), injectables, diagnostics and other complementary solutions, today announced that its long-acting botulinum toxin type A product, DAXXIFY (registered trademark in Mainland China 达希斐®), has successfully passed quality testing by the National Institutes of Food and Drug Control of the People’s Republic of China (“NIFDC”). This milestone confirms that DAXXIFY meets the rigorous requirements set by China’s national drug regulatory system for quality, safety and efficacy, successfully completing the final critical step towards market launch.
DAXXIFY is the world’s first and only long-acting peptide neuromodulator containing the active pharmaceutical ingredient botulinum toxin type A (DaxibotulinumtoxinA). It is also the first and only botulinum toxin type A product approved in mainland China, featuring proprietary Peptide Exchange Technology (PXT) and a stabilized peptide formulation. Designed to provide both long-lasting effect and rapid onset of action, DAXXIFY aims for the temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. Currently, Sisram has concluded initial commercial orders with several leading medical-aesthetic institutions, fully validating the market expectations and recognition of this innovative long-acting product and marking its transition from the preparation phase to the sales phase.
To advance the commercialization of DAXXIFY, the Company has established a comprehensive professional team responsible for market expansion, clinical support and supply chain management. The experienced sales and marketing team continues to cultivate core medical networks, deepening strategic collaborations with medical aesthetic institutions. A dedicated medical affairs team enables physicians to deliver standardized and precise treatments through systematic training programs and clinical evidence generation. In the area of operations and supply chain management, the company has partnered with industry leaders including Fosun Wanbang (Jiangsu) and Shanghai Pharmaceuticals to establish an efficient, reliable and fully traceable supply chain system. This collaborative approach ensures that all stages, from production and logistics to final clinical delivery, meet strict standards of quality and compliance, supporting market readiness and building trust within the medical aesthetics community.
Lead a new premium choice in medical aesthetics and fuel the company’s new growth engine
As the first injectable product launched in mainland China, DAXXIFY offers a premium choice for consumers seeking higher quality standards and exceptional aesthetic experiences. This successful test marks the final regulatory step before market launch. Supported by a well-defined differentiation strategy, a structured value system and a robust operational framework, the company believes that DAXXIFY is poised to become the cornerstone of Sisram’s injectable product portfolio and a key driver of the company’s growth. Additionally, the product is poised to support Sisram’s strategic expansion into the injectables sector, creating a “second growth curve” and strengthening the company’s competitiveness through an integrated wellness ecosystem encompassing EBD technologies, injectables, diagnostics and complementary solutions. The team is fully dedicated to the commercialization of DAXXIFY, with the product expected to be available for clinical application soon. Sisram looks forward to providing DAXXIFY to partner institutions across mainland China, enabling a wide range of consumers to benefit from the exceptional effects while reinforcing its commitment to providing diverse and reliable wellness solutions to the market.
About Sisram Medical Ltd.
Sisram Medical Ltd (1696.HK) is a global leader in medical aesthetic solutions with over 25 years of expertise in energy-based devices (EBD). Built on a legacy of innovation and clinical excellence, the Company’s synergistic ecosystem spans EBD technologies, injectables, diagnostics and complementary solutions. Serving customers in more than 110 countries and regions, Sisram offers award-winning products that set new standards in safety, effectiveness and personalized aesthetic care for millions of patients around the world. Majority-owned by Fosun Pharma, Sisram has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017.
For more information, please visit: https://sisram-medical.com/.
Show original content:https://www.prnewswire.com/apac/news-releases/sisram-medical-reports-completion-of-nifdc-testing-for-daxxify-in-china-302652506.html
SOURCE Sisram Medical Ltd
